CD80-Mediated T-Cell Suppression by Cancer Stem-like Cells in Head and Neck Squamous Cell Carcinoma

Area of Science:

• Oncology
• Immunology
• Cancer Stem Cell Biology

Background:

• Neoadjuvant chemoimmunotherapy shows promise for head and neck squamous cell carcinoma (HNSCC).
• Improving patient response rates to this treatment is a critical unmet need.
• Understanding resistance mechanisms is key to enhancing therapeutic efficacy.

Purpose of the Study:

• To investigate mechanisms of poor response to neoadjuvant chemoimmunotherapy in HNSCC.
• To identify strategies for improving treatment outcomes.
• To explore the role of CD80 in HNSCC chemoimmunotherapy resistance.

Main Methods:

• Identification and characterization of cancer stem-like cell (CSC) populations.
• Analysis of CD80 expression in relation to treatment response.
• Functional assays assessing the impact of CD80 modulation on tumor cell behavior.
• Evaluation of CD80 inhibition on immune responses and T cell cytotoxicity.
• Preclinical HNSCC models to assess therapeutic efficacy of CD80 blockade.

Main Results:

• A CD80-high CSC population was enriched in patients with partial response to chemoimmunotherapy.
• CD80 expression correlated with stemness markers (ALDHhighCD44+, BMI1+).
• CD80 knockdown reduced tumor cell stemness, migration, and invasion; overexpression enhanced these.
• CD80 inhibition promoted Th1 immune responses, IL-2 production, and T cell cytotoxicity.
• CD80 blockade reduced tumor burden and increased CD8+ T cell infiltration in preclinical models.

Conclusions:

• CD80 plays a dual role in HNSCC, promoting tumor stemness and malignant phenotype while suppressing antitumor immunity.
• Targeting CD80 can overcome resistance to neoadjuvant chemoimmunotherapy.
• CD80 blockade represents a promising strategy to enhance therapeutic efficacy in HNSCC.